Nurse Practitioner Program year 2023 Reported 2022–2023 Source: CMS Open Payments, 2026 publication

Angela Scott

Nurse Practitioner, Acute Care New Haven, CT Nurse Practitioner

NPI 1114271517 CMS profile 10992529

20 York Street, Cb-2041, New Haven, CT 06510

Open in the dashboard

General payments

$1,047

11 records reported · program years 2022–2023

Research payments

$0

Paid to them · None reported · program years 2022–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Angela Scott of New Haven, CT is reported in the CMS Open Payments database as having received $1,047 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $125 2
2022 General $922 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Scott
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Angela Scott were reported at $0. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Angela Scott Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $123 $38–$327 $132
2022 $922 $130 $44–$369 $149
2023 $125 $144 $49–$410 $160
2024 $0 $146 $48–$433 $164
2025 $0 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2022–2023
  1. Medtronic, Inc. $909 8 payments
  2. Abbott Laboratories $125 2 payments
  3. Amgen Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2023
  1. Food and Beverage $544 7 payments
  2. Travel and Lodging $502 4 payments
Products named General payments · program years 2022–2023
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $125 2 payments
  2. Blincyto $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,695

Median for Nurse Practitioner: 389

Drug cost

$1,369,618

Median for Nurse Practitioner: $21,885

Branded share of claims

26.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Camzyos Mavacamten Brand 79 $634,448
Entresto Sacubitril/Valsartan Brand 222 $248,710
Farxiga Dapagliflozin Propanediol Brand 147 $166,242
Jardiance Empagliflozin Brand 83 $116,677
Eliquis Apixaban Brand 55 $64,975
Xarelto Rivaroxaban Brand 41 $38,167
Tacrolimus Generic 146 $30,481
Lokelma Sodium Zirconium Cyclosilicate Brand 19 $20,977
Sirolimus Generic 24 $15,946
Mycophenolate Mofetil Generic 51 $3,805

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$11,412

Medicare's payments for the services billed

Medicare patients

101

Average age 72

Services billed

188

39 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 64%
Chronic kidney disease 55%
Diabetes 52%
Atrial fibrillation 52%
Arthritis 50%
Depression 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record